Who is sponsoring NCT03272451?

NCT03272451 is sponsored by Beijing Luhe Hospital.

What drugs are being tested in NCT03272451?

Interventions in NCT03272451: culprit vessel intervention, traditional approach.

What condition does NCT03272451 study?

NCT03272451 studies Myocardial Infarction.

Is NCT03272451 still recruiting?

NCT03272451 is currently completed. Last updated 1 June 2022.

Last reviewed 2022-06-01 · How we verify

NCT03272451

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

ECG-guided Immediate Primary PCI for Culprit Vessel to Reduce Door to Device Time

Completed NA Last updated 1 June 2022

What this trial tests

NA trial testing culprit vessel intervention in Myocardial Infarction in 560 participants. Completed in 31 July 2019.

Timeline

10 February 2017

Primary endpoint
15 July 2019

31 July 2019

Quick facts

Lead sponsor	Beijing Luhe Hospital
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	560
Start date	10 February 2017
Primary completion	15 July 2019
Estimated completion	31 July 2019
Sites	2 locations across China

Drugs / interventions tested

culprit vessel intervention
traditional approach

Conditions studied

Myocardial Infarction — all drugs for Myocardial Infarction →

Sponsor

Beijing Luhe Hospital

Who can join

18 and older, any sex, with Myocardial Infarction. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

No consensus exists about which coronary artery should be firstly catheterized in primary percutaneous coronary intervention (PCI). The aim of the present study was to compare door-to-balloon time (D2B) of ECG guided immediate infarct-related artery (IRA) PCI with traditional complete coronary angiography followed by PCI for the treatment of ST segment elevation myocardial infarction (STEMI) patients. Primary endpoint is door to device (D2D) time. Secondary end-points are: puncture to device (P2D) time,first medical contact to device (FMC2D) time,incidence of radial artery spasm and occlusion, contrast amount, fluoroscopy time, cumulative air kerma(CAK) and dose area product(DAP).

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Culprit vessel revascularization first with primary use of a dedicated transradial guiding catheter to reduce door to balloon time in primary percutaneous coronary intervention.
Guo J, Wang G, Li Z, Liu Z, et al · · 2022 · cited 4× · PMID 36386357 · DOI 10.3389/fcvm.2022.1022488

Verify or expand the search:

Other recruiting trials for Myocardial Infarction

Currently open trials in the same condition.

NCT07257198 — Aspirin-free Strategy With Ticagrelor in Patients With a Myocardial Infarction Treated Medically Alone · Phase 3 · recruiting
NCT07402642 — Effect of Early Educational Intervention on Cardiovascular Risk Factors After Acute Coronary Syndrome · NA · recruiting
NCT07301034 — A Research Study to Look at the Effect of Ziltivekimab on Plaque in the Blood Vessels of the Heart, Compared to Placebo, · Phase 3 · recruiting
NCT07142265 — Evaluation of 1-Year Clinical Outcomes With Early Inclisiran Initiation in Post-MI Patients · recruiting
NCT07138911 — Effect of Home-based Exercise Plan Mediated by Use of Digital Health App on Kinesiophobia and Functional Capacity · NA · recruiting

Other Beijing Luhe Hospital trials

Trials by the same sponsor.

NCT06364124 — Effects of PCSK-9 Inhibitor Treatment Prior to Undergoing Primary Percutaneous Coronary Intervention in Patients With ST · NA · recruiting
NCT05461781 — Distal Radial Access for Primary PCI in STEMI Patients to Prevent RAO · NA · completed
NCT04078451 — Study of Left Side of Laparoscopic Cholecystectomy · NA · unknown
NCT05266547 — Impact of OCT on Outcomes in AMI · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03272451 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Beijing Luhe Hospital
Last refreshed: 1 June 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03272451.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing